Phase 2 study of high dose cytarabine and zanubrutinib for refractory or relapsed primary central nervous system lymphoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039229

Enrollment

Unknown

Registered

2020-10-22

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary central nervous system lymphoma

Interventions

treatment group:high dose cytarabine and zanubrutinib

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 and =3.5g/m2) or relapse after complete remission has been achieved; 4. Willing to accept high dose cytarabine and zanubrutinib.

Exclusion criteria

Exclusion criteria: 1. Had received high dose cytarabine or ibrutinib treatment before; 2. Active infection such as HIV,acute hepatitis,tuberculosis, pulmonary fungi infection; 3. Decompensated cirrhosis or ALT/AST >= 3*ULN; 4. eGFR<30ml/min(Cockcroft-Gault); 5. Severe heart failure (LVEF < 50% or NYHA III/IV); history of atrial fibrillation; 6. Neutrophil < 1.0*10^9/l or platelet < 50*10^9/l; 7. Uncontrolled hemorrhage of digestive tract; 8. Cerebral hemorrhage within 1 year.

Design outcomes

Primary

Measure	Time frame
progressio free survival ;	—

Secondary

Measure	Time frame
response rate;OS;	—

Countries

China

Contacts

Public ContactChen Bobin

Huashan Hospital, Fudan University

zhiguang_lin@163.com+86 13402186236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026